Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Cephalon extends pain relief portfolio

Cephalon : 23 August, 2007  (New Product)
Cephalon is to acquire the North American rights to Amrix (cyclobenzaprine hydrochloride extended-release capsules) from ECR Pharmaceuticals.
Two dosage strengths of Amrix (15mg and 30mg) were approved in February 2007 by the US Food and Drug Administration (FDA) for short-term use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

The product is not yet available commercially in the USA; however, Cephalon expects to launch the product early in the fourth quarter.

Under the agreement, which is expected to close on or about August 28, 2007, Cephalon will acquire the rights to Amrix for $100 million cash. The company also could make future cash payments to ECR upon the achievement of certain cumulative net sales milestones.

'Amrix is an excellent strategic fit with our current sales organization, providing us with a second product that is complementary to many pain relievers used today,' said Robert Roche, executive Vice President, Worldwide Pharmaceutical Operations. '

Cyclobenzaprine HCl is the most widely prescribed muscle relaxant in the USA, representing 37 percent of the 45 million prescriptions for muscle relaxants written in 2006, according to IMS. Amrix has convenient once-daily dosing and a side effect profile that includes very low rates of sedation which will provide physicians and patients an attractive alternative to current therapies.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo